FOI release
Request for information - Ref: FOI2026/00039
Some or all of the information requested was not provided because we didn't hold it.
Case reference FOI2026/00153
Received 13 February 2026
Published 31 March 2026
Request
I request the following information held by the Medicines and Healthcare products Regulatory Agency (MHRA): 1. Oncology-Related Risk Assessments Please confirm whether the MHRA conducted, commissioned, or received any internal risk assessment, briefing paper, or expert review between January 2019 and December 2023 concerning potential interactions between SARS-CoV-2 spike protein expression (including mRNA or adenovirus vector platforms) and: • p53 pathway modulation • BRCA1/BRCA2 pathways • DNA damage response mechanisms • tumour suppressor gene regulation • immune surveillance impairment • cancer progression or recurrence If such documents exist, please provide: a) The title of each document b) The date of creation c) The authoring department or committee d) Any executive summary or conclusion section If no such assessment was conducted, please confirm that fact. 2. Comparative Platform Safety Assessment Please confirm whether the MHRA conducted any comparative safety assessment between: • mRNA vaccine platforms • Adenovirus vector platforms • Inactivated whole-virus platforms Specifically in relation to long-term oncological risk or tumour-suppressor interaction. If such comparative assessments were conducted, please provide: a) The title and date of the assessment b) Minutes of any committee meeting where comparative oncological safety was discussed c) Any formal risk classification outcome If no comparative oncological assessment was conducted, please confirm that fact. 3. Cancer Patient Guidance Consideration Please confirm whether the MHRA formally considered issuing guidance specific to cancer patients or oncology consultation prior to administration of COVID-19 vaccines. If such consideration occurred, please provide: a) Records of internal discussions b) Committee minutes c) Draft guidance documents d) Any risk-benefit analysis specific to oncology patients If no such consideration occurred, please confirm that fact. Clarification and Cost Limit This request is limited to formal assessments, briefing papers, committee minutes, or executive summaries. It does not require a full keyword search across all correspondence. If you consider any part of this request likely to exceed the appropriate cost limit under Section 12, please advise under your duty pursuant to Section 16 how the request may be refined to fall within statutory limits.
Response
See attached
Documents
This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.
You can browse our other responses or make a new FOI request.